Abstract:In a pancreatic tumor microenvironment, activated pancreatic stellate cells (PSCs) produce extracellular matrix (ECM) to form a barrier to drug penetration. Moreover, the interaction between cancer cells and activated PSCs promotes the tumor growth. Vitamin D receptor (VDR), as a key regulator to promote the recovery of PSCs to the resting state, is an attractive therapeutic target for pancreatic cancer. Herein, we reported the design and synthesis of 57 nonsecosteroidal VDR modulators based on the skeleton of phenyl-pyrrolyl pentane. Among them, compounds C4, I5, and I8 exhibited excellent VDR affinity and effective inhibition of the activation of PSCs, as well as potent suppression of the interaction between cancer cells and PSCs in vitro. In vivo, compound I5 combined with gemcitabine achieved efficacious antitumor activity without causing hypercalcemia. In conclusion, the compounds designed in our study can remodel the tumor microenvironment and are expected to be candidates for the treatment of pancreatic cancer.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c01197?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01197</a>.(Table S1) Cell toxicity of all target compounds against LTC-14; (Figure S1) cell toxicity of representative compounds against DSL-6A/C1 cells; (Figure S2) relative BLI intensities of mice that received different treatments; (Figure S3) inhibition rate of tumor growth after tumor-bearing mice received different treatments; (Figure S4) relative fluorescence intensities of α-SMA after mice received different treatments; (Figure S5) survival percentages of mice that received different treatments; (Figure S6) in vivo hypercalcemic effects in the orthotopic transplantation pancreatic cancer model; NMR spectra information; HPLC traces; and 1H NMR and 13C NMR spectra (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01197/suppl_file/jm0c01197_si_001.pdf">PDF</a>)Molecular Formula Strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01197/suppl_file/jm0c01197_si_002.csv">CSV</a>)This article has not yet been cited by other publications.

Supplementary Figures 1-9 from Combined Treatment of Pancreatic Cancer with Mithramycin A and Tolfenamic Acid Promotes Sp1 Degradation and Synergistic Antitumor Activity

Combined Treatment of Pancreatic Cancer with Mithramycin A and Tolfenamic Acid Promotes Sp1 Degradation and Synergistic Antitumor Activity

Supplementary Figures 1-6 from Combining Betulinic Acid and Mithramycin A Effectively Suppresses Pancreatic Cancer by Inhibiting Proliferation, Invasion, and Angiogenesis

In vitro synergistic cytotoxic effect of triptolide combined with hydroxycamptothecin on pancreatic cancer cells.

Supplementary Figures 1 Through 5 from Synergistic Activities of MET/RON Inhibitor BMS-777607 and Mtor Inhibitor AZD8055 to Polyploid Cells Derived from Pancreatic Cancer and Cancer Stem Cells

Supplementary Figure Legend from Synergistic Activities of MET/RON Inhibitor BMS-777607 and Mtor Inhibitor AZD8055 to Polyploid Cells Derived from Pancreatic Cancer and Cancer Stem Cells

Supplementary Methods, Figures 1-3 from Synergistic Antitumor Activity of Gemcitabine and ABT-737 in Vitro and in Vivo Through Disrupting the Interaction of USP9X and Mcl-1

Supplementary Table 3 from Synergistic Activities of MET/RON Inhibitor BMS-777607 and Mtor Inhibitor AZD8055 to Polyploid Cells Derived from Pancreatic Cancer and Cancer Stem Cells

Supplementary Table 2 from Synergistic Activities of MET/RON Inhibitor BMS-777607 and Mtor Inhibitor AZD8055 to Polyploid Cells Derived from Pancreatic Cancer and Cancer Stem Cells

Molecular Basis Of The Synergistic Antiangiogenic Activity Of Bevacizumab And Mithramycin A

Supplementary Figure.5 from the Tautomerase Activity of Tumor Exosomal MIF Promotes Pancreatic Cancer Progression by Modulating MDSC Differentiation

The Underlying Molecular Mechanism of Intratumoral Radiofrequency Hyperthermia-Enhanced Chemotherapy of Pancreatic Cancer

Novel Nonsecosteroidal Vitamin D Receptor Modulator Combined with Gemcitabine Enhances Pancreatic Cancer Therapy through Remodeling of the Tumor Microenvironment

Combination therapy with interleukin-15 and metformin as a synergistic treatment for pancreatic cancer

Supplementary Figure.2 from the Tautomerase Activity of Tumor Exosomal MIF Promotes Pancreatic Cancer Progression by Modulating MDSC Differentiation

Antitumor Effects of 10058-F4 and Curcumin in Combination Therapy for Pancreatic Cancer In Vitro and In Vivo

Supplementary Figure.3 from the Tautomerase Activity of Tumor Exosomal MIF Promotes Pancreatic Cancer Progression by Modulating MDSC Differentiation

Therapeutic inhibition of Sp1 expression in growing tumors by mithramycin a correlates directly with potent antiangiogenic effects on human pancreatic cancer.

Sequential Delivery of Nanoformulated Α-Mangostin and Triptolide Overcomes Permeation Obstacles and Improves Therapeutic Effects in Pancreatic Cancer.

Supplementary Methods, Figures 1-15 from SM-164: A Novel, Bivalent Smac Mimetic That Induces Apoptosis and Tumor Regression by Concurrent Removal of the Blockade of Ciap-1/2 and XIAP

Synergistic Blocking of RAS Downstream Signaling and Epigenetic Pathway in KRAS Mutant Pancreatic Cancer.